There is a recent and growing resurgence of interest in the potential for psychedelic compounds to be utilized as treatments for mood and anxiety disorders when administered in the context of a psychotherapeutic regimen. Chief among the substances most extensively studied is psilocybin, a compound originally derived from a genus of mushrooms that occurs naturally in most continents across the world. Learn more about the research behind them.
ADAA is proud to offer resources for mental health professionals. Find additional tools and information:
- Visit the ADAA website: [ Ссылка ]
- View upcoming professional webinars and events: [ Ссылка ]
- Subscribe to ADAA’s bi-weekly professional newsletter: [ Ссылка ]
- The Anxiety and Depression Association of America (ADAA), a non-profit organization, leads in education, training, and research for anxiety disorders, depression, PTSD, OCD, and co-occurring disorders. ADAA also provides free evidence-based mental health information and resources to the public.
Chapters:
0:00 Introduction
2:07 Objectives
3:18 What is psilocybin
7:44 History of psilocybin
14:02 Structure of Psilocybin-assisted Psychotherapy
19:50 Commonalities and Differences with Existing Therapy Approaches
21:19 First Evidenced Based Study
28:54 Challenges of Research
31:06 Second Evidenced Based Study
33:40 Psilocybin Mystical Experience
38:30 Major Depressive Disorder and Psilocybin
51:00 Therapeutic Mechanisms for Psilocybin
1:00:05 Summary and Recommendations
1:03:50 Q&A
